Sun Pharma Signs Deal with AstraZeneca to Prepare Oncology Products for China


Nov. 06/11 – With an aim to bring quality and cost effective drugs in China, India’s Sun Pharmaceutical Industries Ltd signed an agreement with AstraZeneca UK Ltd a kind of ready-to-use oncology products. 

According to the treaty, Sun Pharma will take care of development, regulatory filings and manufacturing the products while AstraZeneca will exclusively be responsible for promotion and distribution of these products in China. 

The contract will be active for a period of 10 years dated from the first commercial sale of the products in the country, while its financial terms are kept confidential, the company said. 

“We see a great potential to introduce our specialty and generics products in the growing China market and this licensing agreement is another positive step in that direction,” the firm said in a statement. 


About Author

Leave A Reply